Dabrafenib and Lovastatin

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Dabrafenib may alter the blood levels of lovastatin. However, there is currently not enough information to determine whether the levels would increase or decrease, or whether there would be any impact on the clinical effects of lovastatin. Talk to your doctor or pharmacist if you have any questions or concerns. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Let your doctor know immediately if you have unexplained muscle pain, tenderness, or weakness during treatment with lovastatin or similar medications, especially if these symptoms are accompanied by fever or dark colored urine. You should also seek immediate medical attention if you develop fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage related to the use of medications like lovastatin. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration with dabrafenib may alter the pharmacokinetics of HMG-CoA reductase inhibitors. Dabrafenib has been found in vitro to be an inhibitor of organic anion transporting polypeptide (OATP) 1B1 and 1B3. Since many statins including atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin acid (active metabolite of simvastatin) are thought to be substrates of the hepatic uptake transporters, increased plasma concentrations may be expected during coadministration with dabrafenib, although this has not been studied. On the other hand, dabrafenib has also been reported to be an inducer of CYP450 3A4 and 2C9 in vivo. Reduced plasma concentrations may occur for substrates of these isoenzymes such as atorvastatin, fluvastatin, lovastatin, and simvastatin.

MANAGEMENT: Until more information is available, caution is advised when dabrafenib is prescribed with HMG-Coa reductase inhibitors. Clinical and laboratory monitoring are recommended whenever dabrafenib is added to or withdrawn from therapy, and the statin dosage adjusted as necessary. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.

Dabrafenib

Generic Name: dabrafenib

Brand name: Tafinlar

Synonyms: n.a.

What is Dabrafenib?

Lovastatin

Generic Name: lovastatin

Brand name: Altoprev, Mevacor, Altocor

Synonyms: n.a.

What is Lovastatin?